Login to Your Account

PDL Drops Development Of Zamyl After Phase III Failure

By Kim Coghill

Tuesday, May 21, 2002
Protein Design Labs Inc. decided against further development of Zamyl as an acute myeloid leukemia treatment on news that its Phase III trial failed to show statistical significance. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription